Based on the concept that inhibition of PI3K/AKT pathway may effectively overcome HGF-induced resistance to gefitinib, we hypothesized that bufalin could reverse EGFR-TKIs resistance induced by HGF in EGFR mutant lung cancer. This evidence concerns the gene AKT1 and lung carcinoma.